Thursday, November 12, 2026

EUR/CHF Is 1% Down In The Last 10 Sessions

ViaNews Editorial Team

October 12, 2023

EUR/CHF Is 1% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.07% for the last 10 sessions. At 19:06 EST on Thursday, 12 October, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 0.505% up from its 52-week low and 5.299% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Eur/usd continues to gain near 1.0610, focus on German, US data. According to FXStreet on Wednesday, 11 October, "On the other side, the uptick in German bond yields could limit the advancement of the EUR/USD pair, as market participants anticipate the European Central Bank (ECB) to pause its tightening cycle."
  • Eur/usd forex signal: inverted h&s pattern forms - 10 October 2023. According to DailyForex on Tuesday, 10 October, "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bullish viewBuy the EUR/USD pair and set a take-profit at 1.0650.", "The next EUR/USD news will be the upcoming Federal Reserve minutes and US consumer price index (CPI) data on Thursday. "
  • According to FXStreet on Wednesday, 11 October, "As long as the EUR/USD remains below the 200-day SMA, the potential for sustained downward pressure persists.", "The Euro (EUR) alternates gains with losses against the US Dollar (USD) on Wednesday, motivating EUR/USD to trade without a clear direction around the 1.0600 neighbourhood."
  • Eur/usd technical analysis: general trend is still bearish - 10 October 2023. According to DailyForex on Tuesday, 10 October, "But this trade can come back into action at any time and any bullish EUR/USD event should be viewed as a profit taking event in the opposite direction which is required to rebalance the market from previously extended positions.", "This stopped the EUR/USD pair's recent attempts to move upward towards the 1.0600 level at the end of last week's trading, and it settled lower around the 1.0530 support level at the time of writing the analysis. "
  • Eur/usd finds respite as US yields dip as traders eye US and German inflation data. According to FXStreet on Tuesday, 10 October, "A light economic calendar on both sides of the Atlantic keeps the EUR/USD entertained on US Dollar dynamics and market mood. ", "The drop in German bond yields is capping the EUR/USD advance on the Eurozone front, while the European Central Bank (ECB) is expected to halt its tightening cycle, according to market participants."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com